Welcome to The Myeloma Minutes. This is a living library of credible information for patients of multiple myeloma and their caregivers.
During this episode, Drs Jam and Sally talk about the roles of different healthcare professionals involved in a multiple myeloma care team within the NHS, helping patients and carers understand who does what and when.
As patients, we hear of Multidisciplinary Teams and MDT meetings, but today you'll hear how these work in practice and understand how as a patient you get top class VIP treatment throughout your journey. Plus you'll hear more about the following:
-
Not just one doctor—your care involves a whole team of experts.
-
Discover why a specialist haematologist is central to your treatment.
-
Learn how nurses, pharmacists, and even dietitians play vital roles in your journey.
This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns
ABOUT YOUR HOSTS
Dr. Jam Kothari
Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.
Dr. Sally Moore
Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients. She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.